Company Overview
YD Bio Limited a biopharmaceutical company focuses on blood-based cancer detection and develops stem cell- and exosome-based therapeutics to transform the treatment of spectrum of diseases with unmet medical needs. The company is based in Taipei, Taiwan.
Why Investors Should Care
Revenue has grown at a 30.6% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.34.
Recent Developments
- Dec 2025 Revenue of $596.82K (+16.9% YoY); net profit $-8.31M.
- Trailing 12 Months Year-on-year growth — revenue +95.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 30.6%, profit CAGR -30696.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 30.56% |
| 1 Year: | 95.60% |
Compounded Profit Growth
| 5 Years: | -30,696.45% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -83.76% |
| 6 Months: | -80.33% |
| 3 Months: | -57.45% |
| 1 Month: | -6.06% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)42.12 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 30.6% over 5 years.
CONS
- Earnings shrank at -30696.4% CAGR over 5 years.
- Trading 90.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | YDES YD Bio Ltd | 2.17 | -18.08 | $153.70M | 0.00% | -68.50% | -42.69% | 30.56% | -30,696.45% |
| 2 | LLY Eli Lilly and Company SPX | 1,148.84 | 40.85 | $1.02T | 0.60% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 256.35 | 29.74 | $617.09B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 250.94 | 122.41 | $443.36B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 414.40 | 31.23 | $376.34B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 130.20 | 36.68 | $321.57B | 2.82% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 169.64 | 26.30 | $263.09B | 1.87% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 574.30 | 31.54 | $213.42B | 0.35% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 385.16 | 26.78 | $207.87B | 2.80% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Revenue | 350.13K | 510.36K | 596.82K |
| Cost of Revenue | 196.69K | 355.00K | 429.41K |
| Gross Profit | 153.44K | 155.36K | 167.41K |
| Operating Expenses | 160.56K | 1.62M | 5.44M |
| Operating Income | -7.12K | -1.46M | -5.27M |
| EBITDA | 22.25K | -1.28M | -8.10M |
| Interest Expense | 2.14K | 772 | 0 |
| Pretax Income | 17.65K | -1.39M | -8.31M |
| Tax Provision | 4.09K | 25.08K | -1.53K |
| Net Income | 13.56K | -1.41M | -8.31M |
| Diluted EPS | 0.00 | -0.02 | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Total Assets | 321.21K | 6.86M | 13.78M |
| Current Assets | 271.72K | 3.47M | 9.67M |
| Cash & Equivalents | 87.10K | 3.13M | 6.01M |
| Inventory | 69.40K | 37.34K | 1.88M |
| Receivables | 98.17K | 86.58K | 167.48K |
| Total Liabilities | 298.22K | 273.98K | 16.64M |
| Current Liabilities | 298.22K | 263.06K | 1.64M |
| Long Term Debt | - | - | - |
| Total Debt | 47.58K | 22.27K | 6.76K |
| Total Equity | 22.99K | 6.59M | -2.86M |
| Shares Outstanding | 70.10M | 70.10M | 70.79M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | -55.66K | -1.22M | -6.60M |
| Investing Cash Flow | -290 | -2.90M | -1.44M |
| Financing Cash Flow | 113.89K | 7.11M | 10.87M |
| Capital Expenditure | -290 | -2.91M | -1.44M |
| Free Cash Flow | -55.95K | -4.13M | -8.04M |
| Net Change in Cash | 57.94K | 2.99M | 2.83M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | 43.8% | 30.4% | 28.1% |
| Operating Margin % | -2.0% | -286.5% | -882.7% |
| Net Margin % | 3.9% | -276.6% | -1,392.6% |
| ROE % | 59.0% | -21.4% | 291.0% |
| ROCE % | -30.9% | -22.2% | -43.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Geode Capital Management, LLC | 0.09% | 60.24K | $130.71K |
| 2 | Cerity Partners LLC | 0.05% | 32.41K | $70.32K |
| 3 | Cypress Capital Management, LLC (WY) | 0.04% | 30.69K | $66.60K |
| 4 | Citadel Advisors Llc | 0.03% | 19.45K | $42.21K |
| 5 | UBS Group AG | 0.02% | 11.63K | $25.23K |
| 6 | Wolverine Asset Management, LLC | 0.01% | 4.89K | $10.60K |
| 7 | FMR, LLC | - | 1 | $2 |
| 8 | Morgan Stanley | - | 223 | $483 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for YDES
YDES — Frequently Asked Questions
What is the current share price of YD Bio Ltd (YDES)?
As of 2026-08-02 19:16 PDT, YD Bio Ltd (YDES) trades at $2.17 on NasdaqGM. Its 52-week range is $1.90 to $23.11.
What is the market capitalisation of YDES?
YD Bio Ltd (YDES) has a market capitalisation of $153.70M on NasdaqGM.
What is the P/E ratio of YDES?
YDES trades at a trailing price-to-earnings (P/E) ratio of -18.08. The industry average P/E is 27.41. Its price-to-book (P/B) ratio is 0.47.
What is the return on equity (ROE) of YDES?
YDES has a return on equity (ROE) of -42.69%. Its return on capital employed (ROCE) is -68.50%.
Is YDES a good stock to buy?
This page provides a data-driven analysis of YD Bio Ltd (YDES), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.